- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05201898
Dietary Intervention for Cardiovascular Disease
October 25, 2023 updated by: Wen-Harn Pan, Academia Sinica, Taiwan
Incidence of cardiometabolic disease (CMD) continues to rise, which consumes huge medical resources in Taiwan.
The effectiveness of dietary therapy for CMD has not been locally evaluated in detail.
CVD is an important risk factor for dementia.
At the present time, there is no effective treatment available for dementia.
Early prevention is extremely important.
Our previous studies have shown that Taiwanese dementia protective diet is very similar to cardiovascular prevention and control diet, meaning that effective dietary therapy may not only control CVD but also prevent dementia development.
Therefore, this study intends to document the effects of dietary intervention on cardiovascular disease risk factor control, the long-term outcomes on the occurrence of cardiovascular events, and the maintenance of cognitive function for patients with coronary artery disease.
Study Overview
Status
Terminated
Conditions
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beitou District
-
Taipei, Beitou District, Taiwan, 112
- Taipei Veterans General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Have received percutaneous transluminal coronary artery surgery.
- Stable drug control for more than one month
Exclusion Criteria:
- Suffer from cancer and undergo chemotherapy or surgery within one year.
- Those who have a major illness in hospital within one year.
- Those with kidney disease stage 5 (inclusive) or above
- Those whose life expectancy does not exceed half a year
- Patients with diagnosed dementia
- Those who do not want to be tracked
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: usual medical management
with regular doctor visits every 3 months
|
with regular doctor visits every 3 months
|
|
Experimental: usual medical management+individual dietary consultation
with regular doctor visits every 3 months and dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit
|
with regular doctor visits every 3 months
with regular doctor visits every 3 months and dietitian visits every 3 months
|
|
Experimental: usual medical management+individual dietary consultation+ daily tea drinking
with regular doctor visits every 3 months, dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit, and daily tea drinking
|
with regular doctor visits every 3 months
with regular doctor visits every 3 months and dietitian visits every 3 months
with regular doctor visits every 3 months and dietitian visits every 3 months and daily tea drinking
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in diet quality at Year 1, 2, and 3.
Time Frame: Baseline, year 1, 2 and 3
|
Diet quality is estimated according to the daily intake of nutrients and the distribution of the six food groups, with a qualified food frequency questionnaire. The six food groups include:
|
Baseline, year 1, 2 and 3
|
|
Change from baseline in concentrations of cardiovascular risk factors at Month 6, 12, 18, 24,30, and 36.
Time Frame: Baseline and Month 6, 12, 18, 24, 30, and 36.
|
Cardiovascular risk factors include total cholesterol,triglyceride, low-density lipoprotein ,high-density lipoprotein, uric acid, glucose, HbA1C.
|
Baseline and Month 6, 12, 18, 24, 30, and 36.
|
|
Events of cardiovascular diseases at Year 6.
Time Frame: Year 6.
|
CVD or non-CVD death, stroke, acute myocardial infarction, hospitalization for acute coronary syndrome, hospitalization for coronary intervention surgery, hospitalization for various cardiovascular diseases, hospitalization for heart failure, hospitalization for other CVD diseases, new-onset heart arrhythmia, new-onset peripheral blood vessels block
|
Year 6.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in the dosage of prescribed drugs at Month 6, 12, 18, 24,30, and 36.
Time Frame: Baseline and Month 6, 12, 18, 24, 30, and 36.
|
Prescribed drugs for cardiovascular diseases.
|
Baseline and Month 6, 12, 18, 24, 30, and 36.
|
|
Change from baseline in cardiovascular risk score
Time Frame: Baseline, year 1, 2 and 3.
|
Taiwanese edition of Framingham Risk Score, a 10-year risk score derived as a percentage.
Risk is considered low if the Framingham Risk Score is less than 10%, moderate if it is 10% to 19%, and high if it is 20% or higher.
|
Baseline, year 1, 2 and 3.
|
|
Change from baseline in concentrations of inflammatory markers at Year 1, 2, and 3.
Time Frame: Baseline, year 1, 2 and 3.
|
Inflammatory markers include IL-1β, IL-6, IL-8, IL-10,TNF- α, IFN-γ in blood.
|
Baseline, year 1, 2 and 3.
|
|
Change from baseline in scores of Montreal Cognitive Assessment at Year 1, 2, and 3.
Time Frame: Baseline, year 1, 2 and 3.
|
Scores on the Montreal Cognitive Assessment range from zero to 30.
A score of 26 and higher is considered normal.
|
Baseline, year 1, 2 and 3.
|
|
Change from baseline in scores of Number Cancellation test
Time Frame: Baseline, year 1, 2 and 3.
|
A sub-scale of Alzheimer's Disease Assessment Scale.
Cancellation score = number of targets hit in 45 seconds - (minus) number of errors - (minus) number of times reminded of the task.
|
Baseline, year 1, 2 and 3.
|
|
Change from baseline in the number of digits at Year 1, 2 and 3.
Time Frame: Baseline, year 1, 2 and 3.
|
A digit span task is used to measure working memory's number storage capacity.
Subjects are read a sequence of numbers and asked to repeat the same sequence back to the examiner in order (forward span) or in reverse order (backward span).
The score is the length of the longest correctly repeated sequence.
The maximum number of digits in a sequence is 9 and the minimum number of digits in a sequence is 2. The higher scores mean a better outcome.
|
Baseline, year 1, 2 and 3.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Wen-Harn Pan, Ph.D, Institute of Biomedical Sciences, Academia Sinica
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 23, 2021
Primary Completion (Actual)
February 14, 2023
Study Completion (Actual)
February 14, 2023
Study Registration Dates
First Submitted
December 19, 2021
First Submitted That Met QC Criteria
January 7, 2022
First Posted (Actual)
January 21, 2022
Study Record Updates
Last Update Posted (Actual)
October 27, 2023
Last Update Submitted That Met QC Criteria
October 25, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AS-IRB-BM-19057
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Hull University Teaching Hospitals NHS TrustNot yet recruitingCardiovascular Surgery | Cardiovascular Diseases (CVD)United Kingdom
-
Weill Medical College of Cornell UniversityAmerican Heart AssociationRecruitingCardiovascular | Cardiovascular Health | Cardiovascular (CV) Risk | Cardiovascular Disease (CVD) Risk FactorsUnited States
-
Fu Jen Catholic UniversityRecruitingCardiovascular Disease | Cardiovascular SurgeryTaiwan
-
Medical College of WisconsinNational Center for Complementary and Integrative Health (NCCIH)CompletedCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
IRCCS Policlinico S. DonatoIRCCS San Raffaele; Fondazione Policlinico Universitario Agostino Gemelli IRCCS and other collaboratorsRecruitingCardiovascular Risk | Genetic Cardiovascular RiskItaly
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
Children's Hospital Medical Center, CincinnatiRecruitingCardiovascular Diseases (CVD)United States
Clinical Trials on control:usual medical management
-
Ji Xunming,MD,PhDUnknown
-
Northwestern UniversityUniversity of Chicago; Endeavor HealthRecruitingBenign Prostatic HyperplasiaUnited States
-
Avanos MedicalCompletedSacroiliac Joint PainUnited States
-
J. MoccoUniversity at Buffalo; MOUNT SINAI HOSPITALCompletedIntracranial HemorrhageUnited States
-
Penumbra Inc.CompletedCerebral Hemorrhage | Intracerebral Hemorrhage | Brain Hemorrhage | Cerebral Parenchymal HemorrhageUnited States, Germany, Canada, Austria
-
Zhongming QiuTaizhou First People's Hospital; Xiangtan Central Hospital; Zhangzhou Affiliated... and other collaboratorsRecruiting
-
Amrou SarrajPatient-Centered Outcomes Research InstituteRecruiting
-
Zhongming QiuXiangtan Central Hospital (The Affiliated Hospital of Hunan University)RecruitingAcute Ischemic Stroke From Large Vessel Occlusion | Acute Ischemic Stroke (AIS)China
-
Centre Hospitalier Henri Duffaut - AvignonRecruitingChronic Myelogenous Leukemia - Chronic PhaseFrance
-
Oregon Health and Science UniversityWilliam H. Hurt FoundationRecruitingObesity, ChildhoodUnited States